7. Merck
2013 revenue: $44.033 billion
2012 revenue: $47.267 billion

Merck ($MRK) knew its sales picture last year wouldn't be as pretty as it once was, what with former top-seller Singulair now under siege from copycat drugs. The generic attack on Singulair pulled pharma sales for Merck down 8% to $44 billion, once adjusted for foreign currency issues; full-year global sales of the drug slid 69% to $1.2 billion, continuing the trend that has so far forced a $2.5 billion global restructuring and thousands of layoffs.

But Merck had a couple of bright spots on the pharma side, including Remicade and Simponi, which treat inflammatory diseases. Together, they grew 19% and 15% for the year; on its own, sales of Simponi ballooned 51% for the year to hit $500 million. Respiratory drug Dulera, too, made big gains, stealing market share from GlaxoSmithKline ($GSK) behemoth Advair. It posted a 56% gain for the year, generating $324 million in sales.

On the vaccines side, sales of HPV vax Gardasil swelled 12% in 2013 to reach $1.8 billion, up from $1.6 billion in 2012. Zostavax, for shingles, made strides as well, with revenues picking up by 16% to tally $758 million.

Other units didn't see the same growth, with animal health sinking 1% and a Claritin OTC drop of 12% dragging down the consumer care division. The company is currently evaluating both units to decide their fate; the consumer business in particular has reportedly drawn interest from other pharma giants eager to bolster their own offerings, including Bayer and Novartis ($NVS).

-- Carly Helfand (email | Twitter)

For more:
Special Reports: Top 10 Drug Patent Losses of 2014 - Nasonex, Merck | Top Pharma Companies by 2012 Revenues - Merck
Analysts cheer on Merck's comeback campaign, pumping up blockbuster forecasts
Merck's earnings miss slightly but it was not the 'mega-miss' some anticipated
Merck CEO: We'll decide fate of animal health, consumer biz by year's end
Merck sales slump again, but cost cuts keep earnings coming


Suggested Articles

Pfizer isn't giving up in biosims. This week, it unveiled launches to three Roche blockbusters, with two already on the market.

Novo Nordisk is betting big on GLP-1 Saxenda in its global obesity push, but England's cost watchdog is unimpressed with the drug's long-term outlook.

Tecentriq didn’t show benefit against simple observation at delaying cancer recurrence or death in patients with muscle-invasive urothelial cancer.